- Full-year net sales and earnings demonstrates solid
execution and strength of portfolio
- 2024 guidance3 reflects continued operating
EBITDA1 and margin growth
INDIANAPOLIS, Jan. 31,
2024 /PRNewswire/ -- Corteva,
Inc. (NYSE: CTVA)
("Corteva" or the "Company") today reported
financial results for the fourth quarter and full-year
ended December 31, 2023.
4Q
2023 Results Overview
|
|
Net Sales
|
Loss
from Cont. Ops (After Tax)
|
EPS
|
GAAP
|
$3.71B
|
$(231)M
|
$(0.33)
|
vs. 4Q 2022
|
(3) %
|
(463) %
|
(450) %
|
|
Organic1 Sales
|
Operating EBITDA1
|
Operating EPS1
|
NON-GAAP
|
$3.51B
|
$386M
|
$0.15
|
vs. 4Q 2022
|
(8) %
|
+4 %
|
(6) %
|
FY 2023
Results Overview
|
|
Net Sales
|
Income
from Cont. Ops (After Tax)
|
EPS
|
GAAP
|
$17.23B
|
$941M
|
$1.30
|
vs. FY
2022
|
(1) %
|
(23) %
|
(22) %
|
|
Organic1 Sales
|
Operating EBITDA1
|
Operating EPS1
|
NON-GAAP
|
$16.99B
|
$3.38B
|
$2.69
|
vs. FY
2022
|
(3) %
|
+5 %
|
+1 %
|
Full-Year 2023 Highlights
- Full-year 2023 net sales declined 1% and organic1
sales decreased 3% versus prior year with gains in North America2 and EMEA2
offset by declines in Latin
America and Asia
Pacific.
- Seed net sales grew 5% and organic1 sales increased
7%. Price was up 13% globally, led by continued execution on the
Company's price for value strategy and demand for new technology.
Volume declines were driven by lower corn volumes in Latin America, the exit from Russia, and lower corn planted area in
EMEA2, partially offset by increased corn acres in
North America2.
- Crop Protection net sales declined 9% and organic1
sales decreased 12%. Volume declines, largely in Latin America and North America2, were driven by
strategic product exits, inventory destocking, and delayed farmer
purchases. Price gains reflected pricing for value and strong
execution in response to cost inflation led by
EMEA2.
- GAAP income and earnings per share (EPS) from continuing
operations were $941 million and
$1.30 per share, down 23% and 22%,
respectively, compared to prior year.
- Operating EBITDA1 was $3.38
billion, a 5% improvement over prior. Operating
EPS1 was $2.69 per share,
up 1% compared to prior year.
- Cash provided by operating activities – continuing operations
was $1.8 billion, up 98% compared to
prior year. Free cash flow1,4 was $1.2 billion.
- The Company provided full-year 2024 guidance3 and
expects net sales to be in the range of $17.4 billion to $17.7
billion and Operating EBITDA1 to be in the range
of $3.5 billion to $3.7 billion. Operating EPS1 is
expected to be in the range of $2.70
to $2.90 per share. Cash provided by
operating activities – continuing operations is expected to be in
the range of $2.1 billion to
$2.6 billion. Free cash
flow1,4 is expected to be in the range of $1.5 billion to $2.0
billion.
"Corteva's 2023 results reflect the execution of our value
creation strategy, including its focus on productivity,
differentiated product mix, and cost discipline. This,
alongside stand-out performance from our Seed business, allowed us
to deliver growth in earnings, cash and margin despite an ongoing
imbalance in the global crop protection industry. Overall
agriculture fundamentals remain constructive, with record-setting
demand for grain, oilseeds, meat and biofuels continuing into
2024.
"At Corteva, we see 2024 as another year of strong demand for
our differentiated products and a continued focus on controlling
the controllables, delivering advanced technology to our customers
and generating consistent, incremental value for our shareholders.
We have adjusted the 2025 financial framework based on 2023 results
and the expectation for continued earnings growth and margin
expansion in 2024 and 2025," said Chuck
Magro, Corteva Chief Executive Officer.
Summary of Fourth Quarter 2023
For the fourth quarter ended December
31, 2023, net sales decreased 3% versus
the same period
last year. Organic1 sales declined
8%.
Volume declined 9% versus the prior-year
period, primarily in Latin
America, impacted by ongoing headwinds in the Crop
Protection segment and strategic product exits. Lower Seed volumes
were driven by lower expected planted area and delayed
farmer purchases due to unfavorable weather in Brazil.
Price increased 1% versus prior year, reflecting broad-based
pricing execution in Seed and the continued execution on the
Company's price for value strategy, while managing challenging
market dynamics in Crop Protection.
GAAP income from continuing operations after income taxes
was a loss of $231 million in fourth quarter
2023 compared to a loss of $41 million in
fourth quarter 2022. Operating EBITDA1
for the fourth quarter was $386 million,
up 4% compared to prior year.
|
4Q
|
4Q
|
%
|
%
|
($ in millions, except where noted)
|
2023
|
2022
|
Change
|
Organic1 Change
|
Net Sales
|
$3,707
|
$3,825
|
(3) %
|
(8) %
|
North America
|
$1,497
|
$1,472
|
2 %
|
1 %
|
EMEA
|
$371
|
$362
|
2 %
|
3 %
|
Latin America
|
$1,522
|
$1,681
|
(9) %
|
(21) %
|
Asia Pacific
|
$317
|
$310
|
2 %
|
5 %
|
|
FY
|
FY
|
%
|
%
|
($ in millions, except where noted)
|
2023
|
2022
|
Change
|
Organic1 Change
|
Net Sales
|
$17,226
|
$17,455
|
(1) %
|
(3) %
|
North America
|
$8,590
|
$8,294
|
4 %
|
4 %
|
EMEA
|
$3,367
|
$3,256
|
3 %
|
8 %
|
Latin America
|
$3,906
|
$4,445
|
(12) %
|
(23) %
|
Asia Pacific
|
$1,363
|
$1,460
|
(7) %
|
(2) %
|
Seed Summary
Seed net sales were $1.64
billion in the fourth quarter
of 2023, down from $1.65
billion in the fourth quarter of 2022. The
sales decrease was driven by a 10% decline in volume, partially
offset by a 7% increase in price and a 3% favorable currency
impact.
Lower volumes were driven by lower
expected Safrinha planted area and delayed farmer purchases
due to unfavorable weather in Brazil. The increase in price was broad-based,
driven by strong demand for top technology products, and
strong operational execution across the portfolio.
Segment operating EBITDA was $145
million in the fourth quarter of 2023, an improvement of
104% from the fourth quarter of 2022. Price execution, reduction of
net royalty expense, and ongoing cost and productivity actions more
than offset higher input costs, lower volumes, and the unfavorable
impact of currency. Segment operating EBITDA margin improved
more than 450 basis points versus the prior-year period.
|
4Q
|
4Q
|
%
|
%
|
($ in millions, except where noted)
|
2023
|
2022
|
Change
|
Organic1 Change
|
North America
|
$576
|
$541
|
6 %
|
6 %
|
EMEA
|
$181
|
$167
|
8 %
|
17 %
|
Latin America
|
$790
|
$846
|
(7) %
|
(12) %
|
Asia Pacific
|
$88
|
$92
|
(4) %
|
(3) %
|
Total 4Q
Seed Net
Sales
|
$1,635
|
$1,646
|
(1) %
|
(3) %
|
4Q Seed
Operating
EBITDA
|
$145
|
$71
|
104 %
|
N/A
|
Seed net sales were $9.5 billion
for the full year of 2023, up from approximately $9.0 billion in 2022. The sales increase was
driven by a 13% increase in price,
partially offset by a 6% decline in volume and
a 2% unfavorable currency impact.
The increase in price was broad-based and driven by strong
demand for top technology and operational execution globally, with
global corn and soybean prices up 14% and 7%, respectively. Pricing
actions more than offset currency impacts in EMEA. The decline in
volume was driven by the
2022 decision to exit Russia,
lower corn planted area in EMEA, reduced
summer corn planted area and lower expected Safrinha corn planted
area in Brazil, partially offset by increased corn acres
in North America. Unfavorable
currency impacts were led by the Turkish Lira and the Canadian
Dollar.
Segment operating EBITDA was $2.1 billion,
up 28% from the same period last
year. Price execution, reduction of net royalty
expense, and ongoing cost and productivity actions more than offset
higher commodity and input costs, lower volumes, and the
unfavorable impact of currency.
Segment operating EBITDA margin
improved by approximately 390 basis points
versus the prior-year period.
|
FY
|
FY
|
%
|
%
|
($ in millions, except where noted)
|
2023
|
2022
|
Change
|
Organic1 Change
|
North America
|
$5,768
|
$5,178
|
11 %
|
12 %
|
EMEA
|
$1,622
|
$1,609
|
1 %
|
7 %
|
Latin America
|
$1,637
|
$1,758
|
(7) %
|
(11) %
|
Asia Pacific
|
$445
|
$434
|
3 %
|
10 %
|
Total
FY
Seed Net Sales
|
$9,472
|
$8,979
|
5 %
|
7 %
|
FY Seed
Operating EBITDA
|
$2,117
|
$1,656
|
28 %
|
N/A
|
Crop Protection Summary
Crop Protection net sales were
approximately $2.1 billion
in the fourth quarter of 2023 compared
to approximately $2.2 billion in the fourth
quarter of 2022. The sales decline was driven by an 8% decrease in
volume and a 4% decrease in price, partially offset by a 6%
favorable impact from portfolio.
The decrease in volume was driven by strategic product exits and
channel inventory destocking, primarily in Latin America. Price declines in North America and Latin America were driven by challenging
market dynamics. The portfolio impact was driven by the Biologicals
acquisitions, which added approximately $140
million of net sales.
Segment operating EBITDA was $267 million in the
fourth quarter of 2023, down 20% from the fourth
quarter of 2022. Price and volume declines more than
offset lower input costs, productivity actions, and the
favorable impact from the Biologicals
acquisitions. Segment operating EBITDA margin declined by
235 basis points versus the prior-year period.
|
4Q
|
4Q
|
%
|
%
|
($ in millions, except where noted)
|
2023
|
2022
|
Change
|
Organic1 Change
|
North America
|
$921
|
$931
|
(1) %
|
(2) %
|
EMEA
|
$190
|
$195
|
(3) %
|
(9) %
|
Latin America
|
$732
|
$835
|
(12) %
|
(30) %
|
Asia Pacific
|
$229
|
$218
|
5 %
|
8 %
|
Total 4Q Crop Protection
Net Sales
|
$2,072
|
$2,179
|
(5) %
|
(12) %
|
4Q Crop
Protection
Operating EBITDA
|
$267
|
$332
|
(20) %
|
N/A
|
Crop Protection net sales
were approximately $7.8 billion
in 2023 compared to approximately $8.5 billion in 2022.
The sales decrease was driven by a 14% decrease in volume and a 1%
unfavorable impact from currency. These declines were partially
offset by a 4% favorable impact from portfolio and a 2% increase in
price.
The decrease in volume
was driven by strategic product exits, channel
inventory destocking, and delayed farmer purchases.
The increase in price
was led by EMEA, and mostly reflected pricing
for the value of our differentiated technology, including new
products, and currency in EMEA, partially offset by challenging
market dynamics in Latin America
and North America. Unfavorable currency impacts were led by
the Turkish Lira and Chinese Renminbi. The portfolio impact was
driven by the Biologicals acquisitions, which added approximately
$420 million of net sales.
Segment operating EBITDA was $1.4
billion in 2023, down 18% from prior year. Pricing
execution, productivity actions, and the favorable impact from the
Biologicals acquisitions were more than offset by lower
volumes, higher input costs, and the unfavorable impact of
currency. Segment operating EBITDA margin declined
by 215 basis
points versus the prior-year period.
|
FY
|
FY
|
%
|
%
|
($ in millions, except where noted)
|
2023
|
2022
|
Change
|
Organic1 Change
|
North America
|
$2,822
|
$3,116
|
(9) %
|
(10) %
|
EMEA
|
$1,745
|
$1,647
|
6 %
|
8 %
|
Latin America
|
$2,269
|
$2,687
|
(16) %
|
(30) %
|
Asia Pacific
|
$918
|
$1,026
|
(11) %
|
(6) %
|
FY Crop
Protection
Net
Sales
|
$7,754
|
$8,476
|
(9) %
|
(12) %
|
FY Crop
Protection
Operating EBITDA
|
$1,374
|
$1,684
|
(18) %
|
N/A
|
2024 Guidance
The global outlook for agriculture remains constructive overall
in 2024. There was record-setting demand for grain, oilseeds, and
biofuels in 2023 and we expect that to continue to grow in 2024.
On-farm demand remains steady and overall strong. The Crop
Protection industry is working to rebalance after the significant
destocking in 2023, however we expect the industry to modestly
improve as the imbalance between product going into the channel and
on-farm consumption returns to alignment.
The Company provided guidance3 for the full-year
2024. Corteva expects net sales in the range of $17.4 billion to $17.7
billion, growth of 2% at the mid-point. Operating
EBITDA1 is expected to be in the range of $3.5 billion to $3.7
billion, growth of 6% at the mid-point. Operating
EPS1 is expected to be in the range of $2.70 to $2.90 per
share, up 4% at the mid-point, which reflects higher earnings
partially offset by interest expense and a higher base tax rate.
Cash provided by operating activities – continuing operations is
expected to be in the range of $2.1
billion to $2.6 billion.
Free cash flow1,4 is expected to be in the range of
$1.5 billion to $2.0 billion. The Company plans to
repurchase approximately $1.0 billion
shares in 2024.
The Company is not able to reconcile
its forward-looking non-GAAP
financial measures to its most comparable U.S. GAAP financial
measures, as it is unable to predict with reasonable certainty
items outside of its control, such as Significant Items, without
unreasonable effort.
Fourth Quarter Conference Call
The Company will host a live webcast of its fourth quarter 2023
earnings conference call with investors to discuss its
results and outlook tomorrow, February
1, 2024, at 9:00 a.m. ET. The slide presentation that accompanies the conference call is posted
on the Company's Investor Events
and Presentations page. A replay of
the webcast will also be available on the
Investor Events and Presentations page.
About Corteva
Corteva, Inc. (NYSE: CTVA) is a global pure-play agriculture
company that combines industry-leading innovation, high-touch
customer engagement and operational execution to profitably deliver
solutions for the world's most pressing agriculture challenges.
Corteva generates advantaged market preference through its unique
distribution strategy, together with its balanced and globally
diverse mix of seed, crop protection, and digital products and
services. With some of the most recognized brands in agriculture
and a technology pipeline well positioned to drive growth, the
Company is committed to maximizing productivity for farmers, while
working with stakeholders throughout the food system as it fulfills
its promise to enrich the lives of those who produce and those who
consume, ensuring progress for generations to come. More
information can be found at www.corteva.com.
Cautionary Statement About
Forward-Looking Statements
This report contains certain estimates and forward-looking
statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and Section 27A
of the Securities Act of 1933, as amended, which are intended to
be covered by the safe harbor provisions for forward-looking
statements contained in the Private Securities Litigation Reform
Act of 1995, and may be identified by their use of words like
"plans," "expects," "will," "anticipates," "believes,"
"intends," "projects," "estimates," "outlook," or other words
of similar meaning. All statements that address expectations or
projections about the future, including statements about
Corteva's financial results or outlook; strategy for growth;
product development; regulatory approvals; market position;
capital allocation strategy; liquidity; environmental, social and
governance ("ESG") targets and initiatives; the anticipated
benefits of acquisitions, restructuring actions, or cost savings
initiatives; and the outcome of contingencies, such as litigation
and environmental matters,
are forward-looking statements.
Forward-looking statements and other estimates are based on
certain assumptions and expectations of future events which may not
be accurate or realized. Forward-looking statements and other
estimates also involve risks and uncertainties, many of which are
beyond Corteva's control. While the list of factors presented below
is considered representative, no such list should be considered to
be a complete statement of all potential risks and uncertainties.
Unlisted factors may present significant additional obstacles to
the realization of forward-looking statements. Consequences of
material differences in results as compared with those anticipated
in the forward-looking statements could include, among other
things, business disruption, operational problems, financial loss,
legal liability to third parties and similar risks, any of which
could have a material adverse effect on Corteva's business, results
of operations and financial condition. Some of the important
factors that could cause Corteva's actual results to differ
materially from those projected in any such forward-looking
statements include: (i) failure to obtain or maintain the
necessary regulatory approvals for some of Corteva's products; (ii)
failure to successfully develop and commercialize Corteva's
pipeline; (iii) effect of the degree of public understanding and
acceptance or perceived public acceptance of Corteva's
biotechnology and other agricultural products; (iv) effect of
changes in agricultural and related policies of governments and
international organizations; (v) costs of complying with evolving
regulatory requirements and the effect of actual or
alleged violations of environmental laws or permit
requirements; (vi) effect of climate change and unpredictable
seasonal and weather factors; (vii) failure to comply with
competition and antitrust laws; (viii) effect of competition in
Corteva's industry; (ix) competitor's establishment of an
intermediary platform for distribution of Corteva's products; (x)
impact of Corteva's dependence on third parties with respect to
certain of its raw materials or licenses and commercialization;
(xi) effect of volatility in Corteva's input costs; (xii) risk
related to geopolitical and military conflict; (xii) risks related
to environmental litigation and the indemnification obligations of
legacy EIDP liabilities in connection with the separation of
Corteva; (xiv) risks related to Corteva's global operations; (xv)
failure to effectively manage acquisitions, divestitures,
alliances, restructurings, cost savings initiatives, and other
portfolio actions; (xvi) effect of industrial espionage and other
disruptions to Corteva's supply chain, information technology or
network systems;(xvii) failure of Corteva's customers to pay their
debts to Corteva, including customer financing programs; (xviii)
failure to raise capital through the capital markets or short-term
borrowings on terms acceptable to Corteva; (xix) increases in
pension and other post-employment benefit plan funding obligations;
(xx) capital markets sentiment towards ESG matters; (xxi) risks
related to pandemics or epidemics; (xxii) Corteva's intellectual
property rights or defense against intellectual property claims
asserted by others; (xxiii) effect of counterfeit products; (xxiv)
Corteva's dependence on
intellectual property cross-license agreements; and
(xxv) other risks related to
the Separation from DowDuPont.
Additionally, there may be other risks and uncertainties that
Corteva is unable to currently identify or that Corteva does not
currently expect to have a material impact on its business. Where,
in any forward-looking statement or other estimate, an expectation
or belief as to future results or events is expressed, such
expectation or belief is based on the current plans and
expectations of Corteva's management and expressed in good faith
and believed to have a reasonable basis, but there can be no
assurance that the expectation or belief will result or be achieved
or accomplished. Corteva disclaims and does not undertake any
obligation to update or revise any forward-looking statement,
except as required by applicable law. A detailed discussion of some
of the significant risks and uncertainties which may cause results
and events to differ materially from such forward-looking
statements is included in the "Risk Factors" section of Corteva's
Annual Report on Form 10-K, as modified by subsequent Quarterly
Reports on Forms 10-Q and Current Reports on Form 8-K.
Regulation G (Non-GAAP Financial Measures)
This
earnings release includes information that does not conform to U.S.
GAAP and are considered non-GAAP measures. These measures may
include organic sales, organic growth (including by segment and
region), operating EBITDA, operating EBITDA margin, operating
earnings (loss) per share, and base income tax rate. Management
uses these measures internally for planning and forecasting,
including allocating resources and evaluating incentive
compensation. Management believes that these non-GAAP measures best
reflect the ongoing performance of the Company during the periods
presented and provide more relevant and meaningful information to
investors as they provide insight with respect to ongoing operating
results of the Company and a more useful comparison of year over
year results. These non-GAAP measures supplement the Company's U.S.
GAAP disclosures and should not be viewed as an alternative to U.S.
GAAP measures of performance. Furthermore, such non-GAAP measures
may not be consistent with similar measures provided or used by
other companies. Reconciliations for these non-GAAP measures to
U.S. GAAP are provided in the Selected Financial Information and
Non-GAAP Measures starting on page A-5 of the Financial Statement
Schedules.
Corteva is not able to reconcile its forward-looking non-GAAP
financial measures, except for Free Cash Flow, to its most
comparable U.S. GAAP financial measures, as it is unable to predict
with reasonable certainty items outside of the Company's control,
such as Significant Items, without unreasonable effort. For
Significant items reported in the periods presented, refer to page
A-10 of the Financial Statement Schedules. Beginning January 1, 2020, the Company presents accelerated
prepaid royalty amortization expense as a significant item.
Accelerated prepaid royalty amortization represents the non-cash
charge associated with the recognition of upfront payments made to
Monsanto in connection with the Company's non-exclusive license in
the United States and Canada for Monsanto's Genuity® Roundup Ready 2
Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits.
During the ramp-up period of Enlist E3TM, Corteva has begun to
significantly reduce the volume of products with the Roundup Ready
2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits
beginning in 2021, with expected minimal use of the trait platform
thereafter. During 2023, the company committed to restructuring
activities to optimize the Crop Protection network of manufacturing
and external partners, which are expected to be substantially
complete in 2024. The company expects to record approximately
$180 million to $230 million net pre-tax restructuring charges
during 2024 for these activities.
Organic sales is defined as price and volume and excludes
currency and portfolio and other impacts, including significant
items. Operating EBITDA is defined as earnings (loss) (i.e., income
(loss) from continuing operations before income taxes) before
interest, depreciation, amortization, non-operating benefits
(costs), foreign exchange gains (losses), and net unrealized gain
or loss from mark-to-market activity for certain foreign currency
derivative instruments that do not qualify for hedge accounting,
excluding the impact of significant items. Non-operating benefits
(costs) consists of non-operating pension and other post-
employment benefit (OPEB) credits (costs), tax indemnification
adjustments, and environmental remediation and legal costs
associated with legacy businesses and sites. Tax indemnification
adjustments relate to changes in indemnification balances, as a
result of the application of the terms of the Tax Matters
Agreement, between Corteva and Dow and/or DuPont that are recorded
by the Company as pre-tax income or expense. Operating EBITDA
margin is defined as Operating EBITDA as a percentage of net
sales.
Operating earnings (loss) per share is defined as "earnings
(loss) per common share from continuing operations - diluted"
excluding the after-tax impact of significant items, the after-tax
impact of non-operating benefits (costs), the after-tax impact of
amortization expense associated with intangible assets existing as
of the Separation from DowDuPont, and the after-tax impact of net
unrealized gain or loss from mark-to-market activity for certain
foreign currency derivative instruments that do not qualify for
hedge accounting. Although amortization of the Company's intangible
assets is excluded from these non-GAAP measures, management
believes it is important for investors to understand that such
intangible assets contribute to revenue generation. Amortization of
intangible assets that relate to past acquisitions will recur in
future periods until such intangible assets have been fully
amortized. Any future acquisitions may result in amortization of
additional intangible assets. Net unrealized gain or loss from
mark-to-market activity for certain foreign currency derivative
instruments that do not qualify for hedge accounting represents the
non-cash net gain (loss) from changes in fair value of certain
undesignated foreign currency derivative contracts. Upon
settlement, which is within the same calendar year of execution of
the contract, the realized gain (loss) from the changes in fair
value of the non-qualified foreign currency derivative contracts
will be reported in the relevant non-GAAP financial measures,
allowing quarterly results to reflect the economic effects of the
foreign currency derivative contracts without the resulting
unrealized mark to fair value volatility. Base income tax rate is
defined as the effective tax rate excluding the impacts of foreign
exchange gains (losses), non-operating benefits (costs),
amortization of intangibles (existing as of the Separation),
mark-to- market gains (losses) on certain foreign currency
contracts not designated as hedges, and significant items.
The Company also uses Free Cash Flow as a non-GAAP measure to
evaluate and discuss its liquidity position and ability to generate
cash. Free Cash Flow is defined as cash provided by (used for)
operating activities – continuing operations, less capital
expenditures. We believe that Free Cash Flow provides investors
with meaningful information regarding the Company's ongoing ability
to generate cash through core operations, and our ability to
service our indebtedness, pay dividends (when declared), make share
repurchases, and meet our ongoing cash needs for our operations.
The company made the decision, which was retrospectively applied,
to adjust the presentation of the Consolidated Statement of Cash
Flows to separately show the cash provided by (used for) operating
activities – discontinued operations, which was previously
presented within cash provided by (used for) operating activities.
As a result, the definition for Free Cash Flow was revised to
utilize cash provided by (used for) operating activities –
continuing operations. The change in definition did not have a
material impact to prior years' Free Cash Flow. We made this
decision to better present the liquidity generated from our ongoing
business operations. Under the revised definition, Free Cash
Flow was $307 million for the year
ended 2022. For comparability, the prior year's Free Cash Flow
has been updated to reflect this change when determining the
year-over-year changes.
® TM Corteva Agriscience and its affiliated companies.
1. Organic Sales, Operating EPS,
Operating EBITDA and Free Cash
Flow are non-GAAP measures. See page A-5
for further discussion. 2. North
America is defined
as U.S. and Canada. EMEA is defined
as Europe, Middle East and Africa. 3. The Company does not provide
the most comparable GAAP measure on a forward-looking basis. 4. The
definition for Free Cash Flow was revised to utilize cash provided
by (used for) operating activities-continuing operations. See
page 6 for further discussion.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corteva-reports-fourth-quarter-and-full-year-2023-results-provides-2024-guidance-302049891.html
SOURCE Corteva, Inc.